This is a treatment-based clinical trial on celiac disease and Type 1 Diabetes (T1D), conducted in collaboration with Stanford University and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
The study is looking at whether a drinkable study medication helps to relieve the common symptoms suffered by patients with celiac disease and Type 1 Diabetes after accidental gluten contact.
Alongside a gluten-free diet, a therapeutic option, that is designed to decrease symptoms and protect the small intestine, has huge potential impact for those currently suffering from celiac disease.
It is important to research symptoms and treatments in patients with both celiac disease and Type 1 Diabetes because celiac disease occurs at a higher rate in those diagnosed with Type 1 Diabetes.
The dietary restrictions and resulting health consequences of both diseases greatly impact a patient’s quality of life.
We believe that a treatment for celiac disease could greatly forestall and maybe even prevent the onset of celiac disease in children with Type 1 Diabetes.
Up to 8 visits over 34 weeks
blinded, placebo-controlled trial, but all participants will receive the study medication for some period during the study
Primary study measure:
reduction in symptom severity
“latiglutenase”, a combination of enzymes designed to break down gluten in the stomach. Provided as a powdered drink mix to be taken with meals